Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Fig. 3

(a) Rates of ≥50% migraine response by 12-week dosing interval and (b) cumulative 4-week intervals with ≥50% migraine response (efficacy population). *P < 0.001 vs placebo. Nominal P < 0.001 vs placebo (analyses of migraine responder rates over weeks 13–24 were not formally tested per the predefined statistical hierarchy)

Back to article page